Form 4: Tyra Biosciences Officer Reports 8,000 Share Sale

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, reported the sale of 8,000 common shares on December 12, 2025, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel Bensen, Chief Discovery Officer of Tyra Biosciences, Inc., reported the disposition of 8,000 shares of common stock.
• The transaction occurred on December 12, 2025.
• The shares were sold at a weighted average price of $22.6449, with actual sale prices ranging from $22.06 to $23.03.
• Following this transaction, Daniel Bensen beneficially owns 162,981 shares of Tyra Biosciences common stock.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale reduces direct equity, the fact that it was executed under a pre-planned 10b5-1 transaction mitigates concerns about immediate insider sentiment or market timing. It's a routine personal financial management action.

Positives

• The sale was part of a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-scheduled transaction rather than an immediate reaction to new, non-public information.

Negatives

• An insider selling shares, even under a 10b5-1 plan, reduces the insider's direct equity stake, which can sometimes be perceived negatively by the market.

Risks

• Potential negative market perception if investors misinterpret the 10b5-1 plan as a lack of confidence, despite its pre-scheduled nature.
• The actual proceeds from the sale were subject to market fluctuations within the reported range of $22.06 to $23.03.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's operational or financial performance, focusing solely on a reported insider stock transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all industries, including biotechnology. It does not provide specific insights into broader industry trends or competitive landscape for Tyra Biosciences.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May observe a slight reduction in insider ownership, but the 10b5-1 plan context suggests it is a routine transaction rather than a signal of lack of confidence.
• Other stakeholders: No direct impact indicated.

Next Steps

• No specific future actions or milestones are mentioned in relation to this insider transaction, beyond the completion of the reported sale.

Key Dates

Recommendation

The filing details a routine, reported insider stock sale under a Rule 10b5-1 plan. This type of transaction is generally not indicative of a change in the company's fundamental outlook or a lack of insider confidence. Therefore, it does not provide new information that would warrant a change in investment recommendation. Investors should continue to hold based on the company's core business fundamentals rather than this specific insider transaction.

Keywords

Tyra Biosciences, TYRA, Form 4, Insider Trading, Stock Sale, Daniel Bensen, Chief Discovery Officer, 10b5-1 Plan, Biotechnology, SEC Filing